Drug Trial Radar · NCT05141721
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Last checked: Nov 20, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Feb 12, 2022
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Seattle Project CorporationIndustry
- Sponsor type
- Industry
- First posted
- Dec 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (patient-specific vaccines) in combination with checkpoint inhibitors in addition to fluoropyrimidine/bevacizumab versus a fluoropyrimidine/bevacizumab alone as assessed by molecular response which is based on changes in circulating tumor (ct)DNA. The primary objective of the Phase 3 portion is to demonstrate clinical efficacy of the regimen as assessed by progression-free survival.
Conditions
- Colorectal Neoplasms
Interventions
GRT-C901Drug
A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10\^12 viral particles 2 times over the course of the first year.
GRT-R902Drug
A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year.
AtezolizumabDrug
Atezolizumab will be administered via intravenous (IV) infusion at a dose of 1680 mg once every 4 weeks.
IpilimumabDrug
Ipilimumab will be administered via subcutaneous (SC) injection at a dose of 30 mg with the first dose of GRT-C901 and GRT-R902.
Fluoropyrimidine plus leucovorinDrug
Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.
BevacizumabDrug
Bevacizumab administered as maintenance therapy per standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Molecular response defined as ≥ 30% decrease from baseline in circulating tumor DNA (ctDNA)Time frame: Baseline and up to 27 months
- Phase 3: Progression-free survival per Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) as assessed by blinded independent review committee (IRC)Time frame: Up to 60 months
Locations
43 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson
Gilbert, Arizona
Highlands Oncology
Springdale, Arkansas
U.S.C Norris Cancer Center, Keck School of Medicine, Division of Medical Oncology
Los Angeles, California
University of California - Irvine (UCI)
Orange, California
University of California Los Angeles (UCLA)
Santa Monica, California
Rocky Mountain Cancer Centers - USOR
Denver, Colorado
Eastern CT Hematology and Oncology Associates (ECHO)
Norwich, Connecticut
Lynn Cancer Institute - Boca Raton Regional Hospital
Boca Raton, Florida
University of Miami
Miami, Florida
Miami Cancer Institute at Baptist Health South Florida (USOR site)
Miami, Florida
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
Orlando Health
Orlando, Florida
Advanced Research (Oncology & Hemotology Associates of West Broward)
Tamarac, Florida
University of Illinois at Chicago
Chicago, Illinois
University of Chicago
Chicago, Illinois
Indiana University
Indianapolis, Indiana
University of Kansas Medical Center
Fairway, Kansas
Norton Cancer Institute
Louisville, Kentucky
American Oncology Partners of Maryland, PA
Bethesda, Maryland
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Astera Cancer Care
East Brunswick, New Jersey
Summit Health
Florham Park, New Jersey
Morristown Medical Center
Morristown, New Jersey
Rutgers
New Brunswick, New Jersey
NYU Langone Health
New York, New York
Columbia University Irving Medical Center
New York, New York
New York Cancer and Blood
Port Jefferson Station, New York
Christ Hospital Cancer Center
Cincinnati, Ohio
Northwest Cancer Specialists DBA Compass Oncology - USOR
Portland, Oregon
Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, Pennsylvania
Allegheny General Hospital
Pittsburgh, Pennsylvania
Prisma Health
Greenville, South Carolina
Tennessee Oncology - Sarah Cannon Research Institute
Nashville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Texas Oncology PA - USOR
Austin, Texas
Texas Oncology - Dallas Sammons
Dallas, Texas
MD Anderson
Houston, Texas
Baylor Scott and White
Temple, Texas
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.